{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:58:40Z","timestamp":1791568720408,"version":"4.3.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"Supplement_9","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Targeted radionuclide therapy is an emerging therapeutic concept for metastatic cancer that can be considered if a tumor can be delineated by nuclear medicine imaging and also targeted based on the expression of a particular target (thera-nostics). This mode of treatment can also compete with or supplement conventional radiotherapy, for example, if MRI does not fully capture the extent of the disease, including microscopic metastases. Targeted radionuclide therapy for patients with thyroid cancer, with certain somatostatin receptor 2-expressing tumors and with prostate-specific membrane antigen-expressing prostate cancer is approved, and numerous approaches of targeted radionuclide therapy for patients with metastatic cancer are in development (eg, using fibroblast activation protein as a target). Although brain metastases are rare in cancers with approved targeted radionuclide therapies, there is no a priori reason to assume that such treatments would not be effective against brain metastases if the targets are expressed and not shielded by the blood-brain barrier. Here, we discuss the current state of the art and opportunities of targeted radionuclide therapies for patients with brain and leptomeningeal metastases.<\/jats:p>","DOI":"10.1093\/neuonc\/noae192","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:42:09Z","timestamp":1727775729000},"page":"S229-S241","source":"Crossref","is-referenced-by-count":7,"title":["Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential?"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9408-3278","authenticated-orcid":false,"given":"Emilie","family":"Le Rhun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ludwig Maximilians-University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00fcllner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Franceschi","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bellaria Hospital , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-1796","authenticated-orcid":false,"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[{"name":"Center for Integrated Oncology (CIO), Universities of Aachen , Bonn, Cologne, and Duesseldorf ,","place":["Germany"]},{"name":"Institute of Neuroscience and Medicine (INM-3), Research Center Juelich , Juelich ,","place":["Germany"]},{"name":"Department of Neurology, Faculty of Medicine, University Hospital Cologne, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-5310","authenticated-orcid":false,"given":"Philipp","family":"Karschnia","sequence":"additional","affiliation":[{"name":"German Cancer Consortium, Partner Site Munich , Munich ,","place":["Germany"]},{"name":"Department of Neurosurgery, Ludwig-Maximilians-University of Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"IRCCS Istituto Neurologico Mediterraneo Neuromed , Pozzilli ,","place":["Italy"]},{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-9429","authenticated-orcid":false,"given":"Tobias","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, and Comprehensive Cancer Center Vienna, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M","family":"Ellingson","sequence":"additional","affiliation":[{"name":"UCLA Brain Tumor Imaging Laboratory (BTIL), Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"issue":"11","key":"2024121023463346700_CIT0001","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol."},{"issue":"1","key":"2024121023463346700_CIT0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae Insights: Central nervous system cancers, version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"key":"2024121023463346700_CIT0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2021.07.032","article-title":"The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy","volume":"156","author":"Karschnia","year":"2021","journal-title":"Eur J Cancer."},{"key":"2024121023463346700_CIT0004","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejca.2021.12.005","article-title":"Changing characteristics, treatment approaches and survival of patients with brain metastasis: Data from six thousand and thirty-one individuals over an observation period of 30 years","volume":"162","author":"Steindl","year":"2022","journal-title":"Eur J Cancer."},{"issue":"2","key":"2024121023463346700_CIT0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med."},{"issue":"12","key":"2024121023463346700_CIT0006","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"2024121023463346700_CIT0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","article-title":"[177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study","volume":"42","author":"Singh","year":"2024","journal-title":"JCO."},{"issue":"12","key":"2024121023463346700_CIT0008","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"key":"2024121023463346700_CIT0009","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","article-title":"887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol."},{"issue":"3","key":"2024121023463346700_CIT0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/annonc\/mdp334","article-title":"Somatostatin receptor tissue distribution in lung neuroendocrine tumours: A clinicopathologic and immunohistochemical study of 218 \u201cclinically aggressive\u201d cases","volume":"21","author":"Righi","year":"2010","journal-title":"Ann Oncol."},{"issue":"3","key":"2024121023463346700_CIT0011","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/cen.12775","article-title":"Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: Correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores","volume":"83","author":"Diakatou","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"10","key":"2024121023463346700_CIT0012","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1369\/0022155419856900","article-title":"Immunohistochemical expression of somatostatin receptor subtypes in a panel of neuroendocrine neoplasias","volume":"67","author":"Remes","year":"2019","journal-title":"J Histochem Cytochem."},{"issue":"1","key":"2024121023463346700_CIT0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/cancers14010162","article-title":"Correlation of Somatostatin Receptor 1-5 Expression, [68Ga]Ga-DOTANOC, [18F]F-FDG PET\/CT and clinical outcome in a prospective cohort of Pancreatic Neuroendocrine Neoplasms","volume":"14","author":"Majala","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024121023463346700_CIT0014","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.anndiagpath.2018.11.002","article-title":"Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer","volume":"38","author":"Terlevi\u0107","year":"2019","journal-title":"Ann Diagn Pathol."},{"issue":"3","key":"2024121023463346700_CIT0015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1167\/iovs.02-0481","article-title":"Expression of somatostatin receptors in uveal melanomas","volume":"44","author":"Ardjomand","year":"2003","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"8","key":"2024121023463346700_CIT0016","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s12149-021-01627-2","article-title":"Evaluation of F-18 DOPA PET\/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: Comparison with GA-68 DOTA-TATE PET\/CT","volume":"35","author":"Asa","year":"2021","journal-title":"Ann Nucl Med."},{"issue":"10","key":"2024121023463346700_CIT0017","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2967\/jnumed.123.265664","article-title":"68Ga-SSO-120 PET for initial staging of small cell lung cancer patients: A single-center retrospective study","volume":"64","author":"Kersting","year":"2023","journal-title":"J Nucl Med."},{"issue":"9","key":"2024121023463346700_CIT0018","first-page":"e45327","article-title":"Definitive treatment of brain metastases from a neuroendocrine tumor with peptide receptor radionuclide therapy with 177Lutetium DOTATATE: A case report","volume":"15","author":"Zhang","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"2024121023463346700_CIT0019","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-007-0038-6","article-title":"Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review","volume":"11","author":"Goglia","year":"2008","journal-title":"Pituitary"},{"key":"2024121023463346700_CIT0020","doi-asserted-by":"crossref","first-page":"5358545","DOI":"10.1155\/2022\/5358545","article-title":"Prostate-specific membrane antigen as target for neuroimaging of central nervous system tumors. VanBrocklin H, ed","volume":"2022","author":"Stopa","year":"2022","journal-title":"Mol Imaging."},{"issue":"6","key":"2024121023463346700_CIT0021","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apm.12195","article-title":"Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers","volume":"122","author":"Wernicke","year":"2014","journal-title":"APMIS."},{"issue":"8","key":"2024121023463346700_CIT0022","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-018-9878-x","article-title":"Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases","volume":"34","author":"Kasoha","year":"2017","journal-title":"Clin Exp Metastasis."},{"issue":"12","key":"2024121023463346700_CIT0023","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1111\/jcmm.15350","article-title":"Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain","volume":"24","author":"Tanjore Ramanathan","year":"2020","journal-title":"J Cell Mol Med."},{"key":"2024121023463346700_CIT0024","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.tranon.2023.101616","article-title":"The clinical application of 68Ga-PSMA PET\/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer","volume":"28","author":"Pei","year":"2023","journal-title":"Transl Oncol."},{"issue":"12","key":"2024121023463346700_CIT0025","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/cup.13774","article-title":"Prostate-specific membrane antigen expression in melanoma metastases","volume":"47","author":"Snow","year":"2020","journal-title":"J Cutan Pathol."},{"issue":"4","key":"2024121023463346700_CIT0026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/RLU.0000000000000709","article-title":"Detection of brain metastasis with 68Ga-labeled PSMA ligand PET\/CT: A novel radiotracer for imaging of prostate carcinoma","volume":"40","author":"Chakraborty","year":"2015","journal-title":"Clin Nucl Med."},{"issue":"3","key":"2024121023463346700_CIT0027","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/RLU.0000000000005050","article-title":"Cerebral and muscular metastases from prostate adenocarcinoma initially depicted by 177 Lu-PSMA SPECT\/CT","volume":"49","author":"Al-Ibraheem","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2024121023463346700_CIT0028","doi-asserted-by":"crossref","first-page":"24","DOI":"10.25259\/JCIS_52_2021","article-title":"Intracranial metastasis from prostate cancer: Investigation, incidence, and imaging findings in a large cohort of Australian men","volume":"11","author":"McBean","year":"2021","journal-title":"J Clin Imaging Sci."},{"issue":"3","key":"2024121023463346700_CIT0029","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3390\/cancers16030667","article-title":"Head-to-head comparison of [18F]PSMA-1007 and [18F]FDG PET\/CT in patients with triple-negative breast cancer","volume":"16","author":"Andryszak","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"2024121023463346700_CIT0030","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11307-018-1271-2","article-title":"Inconsistent detection of sites of metastatic non-clear cell renal cell carcinoma with PSMA-targeted [18F]DCFPyL PET\/CT","volume":"21","author":"Yin","year":"2019","journal-title":"Mol Imaging Biol."},{"issue":"2","key":"2024121023463346700_CIT0031","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12149-023-01876-3","article-title":"A prospective study of 68Ga-PSMA PET\/CT imaging of HCC as diagnosed on conventional imaging to evaluate for potential 177Lu-PSMA therapy","volume":"38","author":"Shamim","year":"2024","journal-title":"Ann Nucl Med."},{"issue":"8","key":"2024121023463346700_CIT0032","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1007\/s00259-019-04354-z","article-title":"Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617","volume":"46","author":"Sathekge","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024121023463346700_CIT0033","doi-asserted-by":"crossref","first-page":"1352615","DOI":"10.3389\/fimmu.2024.1352615","article-title":"Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: Insights for biomarker development in cancer immunotherapies","volume":"15","author":"Dziadek","year":"2024","journal-title":"Front Immunol."},{"issue":"16","key":"2024121023463346700_CIT0034","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/1759-7714.14579","article-title":"High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma","volume":"13","author":"Yanagawa","year":"2022","journal-title":"Thorac Cancer"},{"issue":"8","key":"2024121023463346700_CIT0035","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1007\/s00259-022-05754-4","article-title":"Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology","volume":"49","author":"Chen","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024121023463346700_CIT0036","first-page":"806","article-title":"Fibroblast activation protein as a potential theranostic target in brain metastases of diverse solid tumours","volume":"55","author":"Zuba\u013e","year":"2023","journal-title":"Pathology (Phila)."},{"issue":"6","key":"2024121023463346700_CIT0037","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.acra.2023.12.002","article-title":"68Ga-DOTA.SA.FAPi as a versatile diagnostic probe for various epithelial malignancies: A head-to-head comparison with 18F-FDG","volume":"31","author":"Chopra","year":"2024","journal-title":"Acad Radiol."},{"issue":"5","key":"2024121023463346700_CIT0038","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.122.264689","article-title":"Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities","volume":"64","author":"Hirmas","year":"2023","journal-title":"J Nucl Med."},{"issue":"3","key":"2024121023463346700_CIT0039","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.123.266652","article-title":"Diagnostic accuracy of 68Ga-FAPI versus 18F-FDG PET in patients with various malignancies","volume":"65","author":"Hirmas","year":"2024","journal-title":"J Nucl Med."},{"issue":"6","key":"2024121023463346700_CIT0040","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/ph15060729","article-title":"[99mTc]Tc-iFAP\/SPECT tumor stroma imaging: Acquisition and analysis of clinical images in six different cancer entities","volume":"15","author":"Vallejo-Armenta","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"22","key":"2024121023463346700_CIT0041","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.3390\/cancers14225566","article-title":"Performance and prospects of [68Ga]Ga-FAPI PET\/CT scans in lung cancer","volume":"14","author":"Borgonje","year":"2022","journal-title":"Cancers"},{"issue":"1142","key":"2024121023463346700_CIT0042","doi-asserted-by":"crossref","first-page":"20220463","DOI":"10.1259\/bjr.20220463","article-title":"Non-oncologic incidental uptake on FAPI PET\/CT imaging","volume":"96","author":"Hotta","year":"2023","journal-title":"BJR"},{"issue":"7","key":"2024121023463346700_CIT0043","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00259-024-06635-8","article-title":"[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET\/CT imaging in patients with various type of metastatic cancers","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"19","key":"2024121023463346700_CIT0044","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024121023463346700_CIT0045","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","article-title":"Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: Efficacy and safety assessment","volume":"51","author":"Yadav","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"2024121023463346700_CIT0046","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular 131 I-3F8 for medulloblastoma","volume":"65","author":"Kramer","year":"2018","journal-title":"Pediatr Blood Cancer."},{"key":"2024121023463346700_CIT0047","first-page":"iii14","article-title":"LMAP-21 Preliminary Clinical Data In The Phase 1\/2a Dose Escalation Trial Of Rhenium (186RE) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM): The respect-lm trial","volume":"5","author":"Youssef","year":"2023","journal-title":"Neurooncol. Adv.."},{"issue":"8","key":"2024121023463346700_CIT0048","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I Trial of 131 I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in Breast Cancer Patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J Nucl Med."},{"key":"2024121023463346700_CIT0049","doi-asserted-by":"crossref","first-page":"114202","DOI":"10.1016\/j.ejca.2024.114202","article-title":"\u201cSymptomatic\u201d melanoma brain metastases: a call for clear definitions and adoption of standardized tools","volume":"208","author":"Le Rhun","year":"2024","journal-title":"Eur J Cancer."},{"issue":"1","key":"2024121023463346700_CIT0050","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae192\/59469653\/noae192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/Supplement_9\/S229\/61000391\/noae192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/Supplement_9\/S229\/61000391\/noae192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T23:47:23Z","timestamp":1733874443000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/Supplement_9\/S229\/7798466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":50,"journal-issue":{"issue":"Supplement_9","published-online":{"date-parts":[[2024,10,1]]},"published-print":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae192","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,1]]}}}